Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
XETRA:6MK
6MK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€77.40 - €125.60
Previous CloseN/A
Volume75.00
Average Volume (3M)9.41K
Market Cap
$223.64B
Enterprise Value€276.94B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)14.1
Beta0.12
Next Earnings
Apr 24, 2025EPS Estimate
2.04Next Dividend Ex-Date
Mar 17, 2025Dividend Yield3.38%
Share Statistics
EPS (TTM)6.23
Shares Outstanding2,526,036,100
10 Day Avg. Volume8,290
30 Day Avg. Volume9,406
Standard Deviation0.06
R-Squared0.04
Alpha0.00793
Financial Highlights & Ratios
PEG Ratio0.00329
Price to Book (P/B)N/A
Price to Sales (P/S)3.63
Price to Cash Flow (P/CF)16.90
P/FCF Ratio16.90
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.34
Enterprise Value/Ebitda10.28
Forecast
1Y Price Target
€108.74Price Target Upside24.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Drug ApprovalThe US FDA granted Breakthrough Therapy Designation to sac-TMT for the treatment of patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Product PerformanceThe ZENITH and HYPERION trial updates support the broad benefit of Winrevair in both late and early PAH patients, potentially increasing its uptake.
Bears Say
Market ChallengesGardasil's Q2 weakness in China likely will not be a temporary effect due to longer lasting political and economic pressures, including China's anti-corruption campaign.
Patent ExpiryMerck may face risk of revenue drops if pipeline drugs fail to deliver before the patent expiry of Keytruda in 2028.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.05% Insiders
21.59% Mutual Funds
15.64% Other Institutional Investors
41.35% Public Companies and Individual Investors
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €77.40 and its highest was €125.60 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $223.64B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Apr 24, 2025 which is in 50 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Feb 04, 2025. The company reported €1.651 earnings per share for the quarter, beating the consensus estimate of €1.544 by €0.107.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €2.991 which represents an annual dividend yield of 3.38%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.04.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,526,036,100 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €1.651 in its last earnings report, beating expectations of €1.544. Following the earnings report the stock price went down -10.822%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in DE:6MK
---
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€108.74 (24.28% Upside)
€108.74 (24.28% Upside)
Blogger Sentiment
Bullish
DE:6MK Sentiment 96%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $141.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.07%
12-Months-Change
Fundamentals
Return on Equity
40.81%
Trailing 12-Months
Asset Growth
9.78%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
6MK Company Deck
---
6MK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with strong performance in key areas like oncology and new product launches, but challenges persist with GARDASIL in China and impacts from Medicare Part D redesign. Although the company remains confident in its long-term growth potential, short-term headwinds are acknowledged.Read More>---
6MK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
---
6MK Stock 12 Month Forecast
Average Price Target
€108.74
▲(24.28% Upside)
Technical Analysis
Best Analysts Covering 6MK
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+16.01%
assigned a buy rating 11 months ago
Copying Robyn Karnauskas's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +16.01% per trade.
---